BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new four-year follow-up results from the Phase 3 GLOW study, which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy.

AbbVie announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia.

MaaT Pharma presented data from the continuing compassionate use program in France for MaaT013 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.

Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT576 for patients with relapsed / refractory multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition.

Oncternal Therapeutics, Inc. announced updated interim clinical data from ongoing Phase 1/2 Study CIRM-0001 in an oral presentation at the American Society of Hematology 2022 Annual Meeting.

Orca Bio presented updated positive clinical data on its lead investigational cell therapy, Orca-T, during an oral presentation at the 64th American Society of Hematology Annual Meeting.

Syndax Pharmaceuticals, Inc. presented updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant and KMT2A rearranged relapsed/refractory acute myeloid or acute lymphoid leukemias.

AlloVir, Inc. announced final data from the Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus specific T cell therapy, for the prevention of clinically significant infections or diseases from six common and devastating viruses in allogeneic hematopoietic cell transplant recipients – adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6 and JC virus.

Innovent Biologics, Inc. announced that clinical data of IBI188 as first-line treatment in newly diagnosed higher risk myelodysplastic syndrome is presented at the 2022 American Society of Hematology Annual Meeting, held Dec 10-13, 2022.